First shared at a recent Japanese Society of Digital
Pathology meeting, the company is forging a global alliance with a
leading US medical institution and other organizations to harness
technology for better patient care and outcomes in
oncology.
TAIPEI, Jan. 22,
2025 /PRNewswire/ -- JelloX Biotech
Inc., a Taiwan-based startup focused on cancer pathology, is
unveiling its vision for AI and 3D digital pathology to advance
patient-centered care. The vision was first detailed publicly by
Dr. Yen-Yin Lin, CEO of JelloX,
during the August 2024 Annual Meeting
of the Japanese Society of Digital Pathology. JelloX continues
to distinguish itself as an early adopter of AI and 3D imaging
applied to cancer pathology.
"Technological advancements and the recent surge in AI have
reshaped the future of healthcare, enabling the extraction of
valuable insights that will have real benefits for patients,"
shared Dr. Lin. "3D pathology can offer at least 50 times more
information than conventional 2D methods, providing pathologists
with a more comprehensive understanding of a tumor's biology. The
power of such a diagnostic tool lies in its ability to help
pathologists stratify and personalize, matching the right patients
with the right treatment at the right time. This ultimately leads
to better prognosis, quality of life, and more patient-centered
care."
Improving patient-centered care with technology
JelloX has previously estimated that 40% of cancer patients
can benefit from AI-analyzed 3D imaging for pathology by expanding
feasibility of treatment options like immunotherapy. Due to the
complexity of cancer and variability between cases, these
technologies hold significant promise for oncology, particularly in
addressing the challenge of limited information from conventional
methods. With the increased sampling rate via 3D imaging analyzed
by AI, pathologists have more actionable insights regarding the
tumor, assisting them in making a wholistic diagnosis.
Patients who were previously excluded from immunotherapy due to
undetected biomarker expressions, resulting from the limitations of
current techniques, may now have a renewed opportunity. With its
improved sensitivity, 3D pathology can not only identify cases
previously classified as "false negatives" but also enable early
cancer detection. This allows for earlier treatment initiation,
leading to an improved quality of life for patients.
For healthcare providers, this means matching the right patients
to the right drugs at the right time. For patients, more precision
for diagnosis, treatment, and timing means lowered risk of
misdiagnosis, minimized patient costs, and better
prognosis—ultimately to more patient-centered care and better
quality of life.
A visionary new platform
Dr. Lin continued: "The fight against cancer is not a one-on-one
battle, so partnerships are crucial to accomplish this. JelloX has
embraced collaboration across countries and industries to build an
AI-powered 3D pathology platform together."
In collaboration with a leading US medical center and other
partners, JelloX is developing a platform that can address multiple
pain points for patients and the healthcare industry. The platform
will leverage JelloX's software, MetaLite®, which recently received
510(k) clearance from the US Food and Drug Administration.
In addition to the benefits for patients, an AI-powered 3D
pathology platform that continuously grows could greatly accelerate
biomarker research and benefit the healthcare industry. Over time,
the platform could continue to grow more precise at cancer
diagnosis as it learns from sample biomarkers paired with
anonymized patient outcome data. Also, as the platform finds novel
biomarkers, it could facilitate development of new technologies and
their commercialization.
About JelloX Biotech Inc.
Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a
startup which focus on advancing cancer pathology through
3D digital imaging and AI technology.
For more information, please
visit: https://jellox.com/en/home/
Logo -
https://mma.prnewswire.com/media/1939619/X_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jellox-aims-to-improve-patient-centered-care-with-ai-powered-3d-digital-pathology-302357094.html
